BMS-279700 is a potent oral activity inhibitor that is part of a new family of aniline 5-azimidazolaquoxaline analogs and has excellent anti-inflammatory activity in vivo, as well as in vitro activity against p56LCK and T cell proliferation, blocking the
BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor. With Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 shows hypertensive effects[1].